Home » Newsletters » BioWorld Science

BioWorld Science

April 3, 2009

View Archived Issues

Novel fentanyl formulations are safe and efficacious in cancer pain

Novel cancer therapeutic compounds claimed by the State University of New Jersey

Merck KGaA describes new tyrosine kinase inhibitors for cancer treatment

Substituted CC-1065 analogues claimed by Syntarga

AstraZeneca claims novel 2-pyrazinylbenzimidazole derivatives for cancer treatment

Bivalirudin reduces major bleeding in women undergoing percutaneous coronary intervention

Intracoronary adenosine has no effect on myocardial perfusion

Valsartan reduces morbidity and mortality in diabetic patients and prevents new-onset diabetes

Estradiol-platinum(II) hybrid molecule compares well to cisplatin in breast cancer xenografts

Sildenafil ameliorates effects of experimental renal ischemia-reperfusion

Sorafenib effective in renal cell carcinoma patients with and without prior nephrectomy

Alexion submits Soliris NDA in Japan in paroxysmal nocturnal hemoglobinuria

FDA places ICA-105665 on partial clinical hold

Mitsubishi Tanabe obtains research and development rights in Asia for EVP-6124

Plethora amends license agreement for PSD-502 for premature ejaculation

Pharmaxis completes first component of phase III trial of Bronchitol in cystic fibrosis

Bioniche completes recruitment in phase III registration clinical trial of Urocidin in cancer

Bayer HealthCare and Genzyme sign new strategic agreement

Compugen reports initial results from CAM model of CGEN-25017 peptide

Strativa acquires worldwide rights to Nascobal nasal spray from QOL

BioCancell receives Israeli approval to initiate phase I/IIa clinical trial of BC-819

Almirall to co-market silodosin with Recordati in Spain

Elan and Wyeth amend bapineuzumab phase III protocol

FDA accepts for filing Xanodyne's NDA for menorrhagia treatment

FDA Advisory Committee finds Onglyza cardiovascular risk profile acceptable

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 7, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...